-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

Benzinga·07/31/2026 12:55:31
Listen to the news
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $39.